Kevin Grogan on Muck Rack

Kevin Grogan

Verified
  • Managing Editor Europe, Commercial, Scrip
Manchester
As seen in: Scrip, MarketWatch, Audible Blog, Pharmaphorum, Financial Advisor, PMLiVE, Citeline, HBW Insight, In Vivo, PharmaTimes, The Pink Sheet and
Managing editor Europe, commercial @PharmaScrip. Interested in #pharma #health #MUFC and old guys who can't sing #Dylan #Cohen
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

EULAR: Novartis Closes In On Final Approval For Cosentyx

|
By Kevin Grogan 
| Scrip
The Swiss major has presented positive data on the big-selling IL-17A inhibitor showing sustained remission versus placebo in twice as many patients suffering from polymyalgia rheumatica. An approval in PMR will add to Cosentyx's already-impressive sales • Source: Shutterstock The Cosentyx story has been one of considerable success for Novartis and the Swiss major has moved closer to securing approval in the final indication for the megablockbuster, polymyalgia rheumatica (PMR).
Open in Who Shared Issue with article?

Spain’s Ona Advances ADCs Into Clinic After Cash Boost

|
By Kevin Grogan 
| Scrip
Fundraising is tricky, especially for European biotechs, but the Barcelona-based firm has just closed an oversubscribed series B which brought in over $86m. Valerie Vanhooren (Ona Therapeutics) Benefitting from the heat surrounding the space, Ona Therapeutics has raised a sizeable amount of cash to advance its pipeline of first-in-class antibody-drug conjugates (ADCs).
Open in Who Shared Issue with article?

ASCO: GSK’s Plans To Unseat Gleevec and Sutent With Velzatinib Advance In GIST

|
By Kevin Grogan 
| Scrip
The KIT inhibitor impresses with early results in the firm's bid to become a leader in gastrointestinal stromal tumors. Having already started its Phase III program for velztinib, GSK has presented very early-stage data evaluating the closely watched KIT inhibitor for advanced gastrointestinal stromal tumours (GIST) which have raised hopes that it could replace Gleevec as the standard of care.
Open in Who Shared Issue with article?
See all 2,043 licensed articles (2,054 Total)

Actions

Share this page

Get in touch with Kevin

Contact Kevin, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified